本文選題：乳腺腫瘤 + APM��； 參考：《新疆醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:觀察女性乳腺癌中Erp57、ERAP1的表達(dá)情況,探討其與乳腺癌各臨床病理指標(biāo)的關(guān)系。方法:收集新疆醫(yī)科大學(xué)附屬腫瘤醫(yī)院石蠟包埋組織標(biāo)本共148例(乳腺癌124例/纖維腺瘤24例),新鮮組織標(biāo)本共48例(乳腺纖維瘤14例/乳腺癌34例),分別采用免疫組化SP法和實(shí)時(shí)熒光定量RT-PCR技術(shù)檢測(cè)乳腺癌和纖維腺瘤組織中Erp57及ERAP1蛋白質(zhì)和轉(zhuǎn)錄表達(dá)水平;采用χ2檢驗(yàn)分析纖維腺瘤和乳腺癌中Erp57及ERAP1表達(dá)差異性;采用列聯(lián)系數(shù)相關(guān)分析Erp57、ERAP1蛋白表達(dá)水平與乳腺癌病理特征的關(guān)系,采用T檢驗(yàn)比較不同乳腺組織各基因轉(zhuǎn)錄表達(dá)水平。結(jié)果:(1)免疫組化顯示:Erp57、ERAP1在乳腺癌中表達(dá)水平均低于纖維腺瘤組,分別為(58.8%/100%、47.5%/83.3%),各組之間具有顯著差異(χ2=15.061,P0.01/χ2=10.328,P0.01);Erp57、ERAP1蛋白質(zhì)表達(dá)與乳腺癌患者的病理分期、組織分級(jí)及腋窩淋巴結(jié)有關(guān)(P均0.05),此外,ERAP1與Ki67陽(yáng)性表達(dá)率、年齡、三陰性有關(guān)(P均0.05)。(2)實(shí)時(shí)熒光定量RT-PCR顯示:Erp57mRNA在纖維腺瘤中表達(dá)水平為(4.90±2.04),在乳腺癌中表達(dá)水平為(6.33±1.36),差異具有統(tǒng)計(jì)學(xué)意義(P0.05),ERAP1在纖維腺瘤中表達(dá)水平為(4.48±1.92),在乳腺癌中表達(dá)水平為(4.48±1.90),差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:(1)Erp57、ERAP1蛋白表達(dá)水平下調(diào)可能是乳腺癌免疫逃逸機(jī)制之一,Erp57、ERAP1蛋白表達(dá)水平降低與乳腺癌臨床病理特征具有相關(guān)性。(2)Erp57蛋白質(zhì)表達(dá)水平降低和轉(zhuǎn)錄表達(dá)下調(diào)變化比較相應(yīng),然而ERAP1轉(zhuǎn)錄表達(dá)水平與乳腺纖維腺瘤比較無(wú)差異性改變。
[Abstract]:Objective: to observe the expression of ERAP1 in female breast cancer and to explore the relationship between the expression of ERAP1 and the clinicopathological indexes of breast cancer. Methods: 148 paraffin-embedded tissue specimens (124 breast cancer / 24 fibroadenoma) and 48 fresh tissue specimens (14 breast fibroma / 34 breast cancer) were collected from Cancer Hospital affiliated to Xinjiang Medical University. Immunohistochemical SP method and real-time fluorescence quantitative RT-PCR were used to detect the expression of Erp57 and ERAP1 protein and transcription in breast cancer and fibroadenoma. The difference of Erp57 and ERAP1 expression in fibroadenoma and breast cancer was analyzed by 蠂 2 test, the relationship between the expression level of Erp57 ERAP1 protein and the pathological characteristics of breast cancer was analyzed by column association number correlation, and the transcriptional expression levels of genes in different breast tissues were compared by T test. Results the expression level of Erp57 ERAP1 in breast cancer was significantly lower than that in fibroadenoma group, which was 58.8 / 100 and 47.57.5and / 83.3, respectively. There was a significant difference between the two groups (蠂 ~ 2 ~ (15) 061n P 0.01 / 蠂 ~ (2) 10.328P ~ (0.011) ERAP1 protein expression and the pathological stage of breast cancer patients. The histological grade and axillary lymph node related P were 0.05%, in addition, the positive expression rate of ERAP1 and Ki67, age, and age, The expression level of Erp57 mRNA in fibroadenoma and breast cancer was 4.90 鹵2.04 and 6.33 鹵1.36, respectively. The difference was statistically significant (P < 0.05). The expression level of ERAP1 in fibroadenoma was 4.48 鹵1.922, and that in breast cancer was 4.48 鹵1.922. The level was 4.48 鹵1.90, and the difference was not statistically significant (P 0.05). Conclusion the down-regulation of Erp57 ERAP1 protein expression level may be one of the mechanisms of immune escape in breast cancer. The decrease of ERAP1 protein expression level is related to the clinicopathological features of breast cancer. The decrease of Erp57 protein expression level and the down-regulation of transcription expression are related to the clinicopathological characteristics of breast cancer. However, there was no difference between ERAP1 transcription and breast fibroadenoma.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王昊天;蔡汶潤(rùn);羅偉;曹旭晨;;雙側(cè)原發(fā)性乳腺癌年輕患者臨床特征與診治探討[J];中華腫瘤防治雜志;2016年10期

2 孫世強(qiáng);延艷;劉民鋒;郭昭澤;葉長(zhǎng)生;;免疫治療:乳腺癌治療新思路[J];實(shí)用醫(yī)學(xué)雜志;2015年24期

3 鮑萍萍;彭鵬;顧凱;吳春曉;黃哲宙;龔楊明;張敏璐;鄭瑩;;不同分子分型乳腺癌長(zhǎng)期預(yù)后及治療對(duì)預(yù)后的影響:上海乳腺癌生存研究[J];中華外科雜志;2015年12期

4 張歡;吳斌;;乳腺癌免疫治療的研究進(jìn)展[J];中華乳腺病雜志(電子版);2015年04期

5 袁智英;陳榮芳;;14332例婦女乳腺病篩查結(jié)果的分析[J];中國(guó)醫(yī)藥指南;2015年20期

6 洪超群;張凡;吳曉;莊軼軒;陳熹鵬;崔玉坤;;雌激素受體陽(yáng)性乳腺癌組織PIMT蛋白表達(dá)臨床意義探討[J];中華腫瘤防治雜志;2015年13期

7 唐夢(mèng)秋;吳世凱;;乳腺癌新輔助化療對(duì)放射治療決策的影響[J];中華乳腺病雜志(電子版);2015年03期

8 覃舒婷;莫軍揚(yáng);周韜;;乳腺癌分子亞型對(duì)新輔助化療療效及預(yù)后的預(yù)測(cè)價(jià)值[J];實(shí)用醫(yī)學(xué)雜志;2015年06期

9 潘蕾蕾;馬俊;方芳;;青年乳腺癌與中老年乳腺癌相關(guān)對(duì)比分析[J];國(guó)際老年醫(yī)學(xué)雜志;2015年02期

10 宋曉;信國(guó)鋒;;乳腺癌術(shù)后內(nèi)乳淋巴結(jié)放射治療效果研究[J];當(dāng)代醫(yī)藥論叢;2015年02期

，

本文編號(hào)：1826102